Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zafirlukast - AstraZeneca

Drug Profile

Zafirlukast - AstraZeneca

Alternative Names: Accolate; Accolate SR; Accoleit; Aeronix; Azimax; ICI 204219; Olmoran; Respix®; Vanticon; Zafirst

Latest Information Update: 14 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Quercis Pharma; Western New England University
  • Class Antiallergics; Antiasthmatics; Tosyl compounds
  • Mechanism of Action Isomerase inhibitors; Leukotriene D4 receptor antagonists; Leukotriene E4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Preclinical Amyotrophic lateral sclerosis; COVID 2019 infections; Neurological disorders

Most Recent Events

  • 19 May 2021 Zafirlukast licensed to Quercis Pharma worldwide for the treatment of several indications, including COVID-19, Amyotrophic Lateral Sclerosis (ALS), and neurological disorders
  • 19 May 2021 Western New England University has patent protection for zafirlukast
  • 19 May 2021 Preclinical trials in Amyotrophic lateral sclerosis in USA, Switzerland (unspecified route) prior to May 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top